5-hydroxy-1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid | 1164336-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-hydroxy-1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid
• CAS: 1164336-04-2
• 化学式: C₁₁H₁₀N₂O₄
• 分子量: 234.211
• InChiKey: IQBRWLPOYHHFPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  84.58
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  4-((S)-2-amino-4-tert-butoxycarbonyl-butyryl)piperazine-1-carboxylic acid ethyl ester 、 5-hydroxy-1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 4-((S)-4-tert-butoxycarbonyl-2-{[5-hydroxy-1-(3-methoxyphenyl)-1H-pyrazole-3-carbonyl]amino}butyryl)piperazine-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  [FR] DÉRIVÉS DE PYRAZOLE-CARBOXAMIDE UTILES EN TANT QU'ANTAGONISTES DE P2Y12

  摘要：

  公开号：

  WO2009080227A3
• 作为产物：
  描述：

  5-hydroxy-1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid ethyl ester 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 以83.2%的产率得到5-hydroxy-1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  发现一种有效、选择性和细胞活性的 m6A 脱甲基酶 ALKBH5 抑制剂

  摘要：

  AlkB 同系物 5 (ALKBH5) 是一种 RNA m 6 A 去甲基化酶，参与基因转录、翻译和代谢的调控，被认为是多种人类疾病，尤其是癌症的有前途的治疗靶点。然而，仍然缺乏强效和选择性的 ALKBH5 抑制剂。在此，我们报告了一类包含 1-aryl-1 H -吡唑支架的新型 ALKBH5 抑制剂，它们是通过基于荧光偏振的筛选、结构优化和构效关系分析获得的。在这些化合物中，20m是最有效的化合物，其在荧光偏振测定中显示出0.021μM的IC 50值。大院20m对 ALKBH5 与 FTO 以及其他 AlkB 亚家族成员表现出高选择性，表明对 ALKBH5 具有良好的选择性。细胞热转移试验 (CETSA) 分析表明，20m可有效稳定 HepG2 细胞中的 ALKBH5。斑点印迹实验表明，20m可以增加完整细胞中的m 6 A 水平。总的来说，20m是一种有效的、选择性的和具有细胞活性的 ALKBH5

  DOI：

  10.1016/j.ejmech.2022.114446

文献信息

• [EN] OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS D'ACIDE 3-HÉTÉROAROYLAMINO-PROPIONIQUE À SUBSTITUTION OXYGÈNE ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2011092187A1

  公开（公告）日：2011-08-04

  The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及公式I的化合物，其中A、D、E、G、R10、R30、R40、R50和R60具有索引声明中指示的含义，这些化合物是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及公式I化合物的制备方法、它们的用途以及包含它们的药物组合物。
• OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：Ruf Sven

  公开号：US20130046004A1

  公开（公告）日：2013-02-21

  The present invention relates to compounds of the formula I, wherein A, D, E, G, R 10 , R 30 , R 40 , R 50 and R 60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A、D、E、G、R10、R30、R40、R50和R60具有权利要求中所示的含义，它们是有价值的药物活性化合物。它们是蛋白酶卡特普西A的抑制剂，可用于治疗动脉硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。本发明还涉及制备式I化合物的方法、它们的用途和包含它们的药物组合物。
• Pyrazole-carboxamide derivatives as P2Y12 antagonists
  申请人：Nazaré Marc

  公开号：US08598179B2

  公开（公告）日：2013-12-03

  The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R1；R2；Z；A；B；D；Q；J；V；G和M具有所述要求中指示的含义。式I的化合物是有价值的药理活性化合物。它们展示出强烈的抗血小板聚集作用，因此具有抗血栓作用，并适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不必要的血小板ADP受体P2Y12激活或需要抑制血小板ADP受体P2Y12的治疗或预防的情况。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的有效成分，并含有它们的制药制剂。
• PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：NAZARÉ Marc

  公开号：US20110039829A1

  公开（公告）日：2011-02-17

  The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; Z; A; B; D; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血小板聚集作用，从而具有抗血栓作用，并适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常适用于存在不良激活血小板ADP受体P2Y12的情况或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。本发明还涉及公式I的化合物的制备过程，它们的使用，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Intermediates for the synthesis of oxygen-substituted 3-heteroaroylamino-propionic acid derivatives
  申请人：SANOFI

  公开号：EP2826772A1

  公开（公告）日：2015-01-21

  The present invention relates to synthesis precursors useful for the preparation of compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the description, which in turn are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.

  本发明涉及用于制备式 I 化合物的合成前体、 其中 A、D、E、G、R10、R30、R40、R50 和 R60 的含义如说明书所示，它们是有价值的药物活性化合物。它们是蛋白酶 cathepsin A 的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾病、肝病或炎症等疾病。